Human Umbilical Cord Mesenchymal Stromal Cell Treatment of Severe COVID-19 Patients: A Three-Month Follow-Up Study Following Hospital Discharge

0
104
In this three-month follow-up study, researchers examined discharged patients who had received human umbilical cord-MSC therapy to assess the safety of this therapy and the health-related quality of life of these patients.
[Stem Cells and Development]
Feng, G., Shi, L., Huang, T., Ji, N., Zheng, Y., Lin, H., Niu, C., Wang, Y., Li, R., Huang, M., Chen, X., Shu, L., Wu, M., Deng, K., Wei, J., Wang, X., Cao, Y., & Yan, J. (2021). Human umbilical cord mesenchymal stromal cell treatment of severe COVID-19 patients: a three-month follow-up study following hospital discharge. Stem Cells and Development. https://doi.org/10.1089/scd.2021.0015 Cite
Abstract